Profile picture of Dr. Gerald J. Holtmann

Gastroenterologist

Australian Flag

Gerald J. Holtmann

Icon representing available degree

MD (Medicine), MBA, FRACP, FRCP, FAHMS

Icon that representing available experience

40 Years Overall Experience

Icon representing available city of this doctor

Woolloongabba

Connect with Gerald J. Holtmann

Quick Appointment for Gerald J. Holtmann

No OPD information available

Services Offered by Gerald J. Holtmann

  • Indigestion

  • Irritable Bowel Syndrome (IBS)

  • Small Bowel Bacterial Overgrowth

  • Viral Gastroenteritis

  • Celiac Disease

  • Cholangitis

  • Colitis

  • Colonoscopy

  • Crohn's Disease

  • Diarrhea

  • Endoscopy

  • Gastroesophageal Reflux Disease (GERD)

  • Malabsorption

  • Sclerosing Cholangitis

  • Achalasia

  • Asthma

  • Barrett Esophagus

  • Chronic Idiopathic Constipation (CIC)

  • Chronic Pancreatitis

  • Cirrhosis

  • Colorectal Cancer

  • COVID-19

  • Exocrine Pancreatic Insufficiency

  • Gastric Bypass

  • Gastrointestinal Bleeding

  • Heartburn

  • Helicobacter Pylori Infection

  • Hemorrhagic Proctocolitis

  • Hepatitis

  • Hepatitis C

  • Larynx Atresia

  • Obesity

  • Peptic Ulcer

  • Peritonitis

  • Pneumonia

  • Secondary Peritonitis

  • Sepsis

  • Severe Acute Respiratory Syndrome (SARS)

  • Spontaneous Bacterial Peritonitis

  • Type 2 Diabetes (T2D)

  • Ulcerative Colitis

About Of Gerald J. Holtmann

Gerald J. Holtmann is a male doctor who helps people with stomach and intestine problems. He treats issues like indigestion, stomach pain, diarrhea, and diseases like Crohn's Disease and Ulcerative Colitis. He also does procedures like colonoscopy and endoscopy to check inside the body.

Dr. Holtmann is good at listening to patients and explaining things clearly. People trust him because he is kind and cares about their health. He stays updated on the latest medical information and research to give the best care to his patients.

Dr. Holtmann works well with other doctors and healthcare professionals. He shares his knowledge and learns from others to help more people. His work has helped many patients feel better and live healthier lives.

One of Dr. Holtmann's important studies is about the connection between the gut and the brain. This research can lead to better treatments for gut and brain problems. He is also running a clinical trial to test a new treatment for Ulcerative Colitis, a serious gut disease.

In summary, Dr. Gerald J. Holtmann is a caring and knowledgeable doctor who helps people with stomach and intestine issues. He works hard to learn new things and collaborate with other medical professionals. His research and treatments have improved the lives of many patients.

Education of Gerald J. Holtmann

  • Medical degree (MD); University of Essen (Germany); 1985

  • Clinical training - Internal Medicine & Gastroenterology; University Hospital Essen (Germany)

  • Fellowship - Gastroenterology; Mayo Clinic, Rochester, USA; 1991

  • MBA (Master of Business Administration); University of South Australia (Adelaide); 2008

  • Fellow, Royal Australasian College of Physicians (FRACP); RACP

  • Fellow, Royal College of Physicians (UK) (FRCP); RCP (UK)

  • Fellow, Australian Academy of Health and Medical Sciences (FAHMS); AAHMS

Memberships of Gerald J. Holtmann

  • Gastroenterological Society of Australia (GESA)

  • Royal Australasian College of Physicians (RACP)

  • Royal College of Physicians (UK)

  • Australian Academy of Health and Medical Sciences (AAHMS)

Publications by Gerald J. Holtmann

Decoding the Gut-Brain Axis: A Journey toward Targeted Interventions for Disorders-of-Gut-Brain Interaction.

Journal: Digestive diseases (Basel, Switzerland)
Year: December 20, 2024
Authors: Gerald Holtmann, Md Moniruzzaman, Ayesha Shah

Description:Background: The gut-brain axis is a bidirectional communication pathway connecting the gastrointestinal tract and the brain. Disorders of gut-brain interaction (DGBI) manifest as highly prevalent gastrointestinal disorders such as irritable bowel syndrome (IBS) or functional dyspepsia (FD). Conclusions: The initial focus of DGBI research was on the effects of psychological stress on digestive functions like gastrointestinal motility, or secretion of gastric acid and pancreatic enzymes. Concepts related to DGBI have expanded in recent decades. Activation of mucosal or systemic immune functions has been observed in DGBI, and it is established that the gastrointestinal microbiome can alter mucosal integrity and permeability, leading to pro-inflammatory cytokine release that affects brain function. Pharmacologic treatments (e.g., tricyclic antidepressants) and non-pharmacologic interventions (e.g., cognitive behavioral therapy) are now standard for DGBI patients. Advances in culture-independent methods to study gastrointestinal microbes reveal new insights into DGBI and gut microbiota appear to play a crucial role in modulating the gut-brain axis and regulating various bodily functions. Conclusions: DGBI are highly prevalent. Research in this field has evolved from studying the effects of psychological stress to recognizing the significant role of the gut microbiome and its metabolites in mucosal integrity and immune responses.

Mechanisms of action and clinical effectiveness of herbal treatments for disorders of gut-brain interaction.

Journal: Digestive And Liver Disease : Official Journal Of The Italian Society Of Gastroenterology And The Italian Association For The Study Of The Liver
Year: March 19, 2025
Authors: Md Moniruzzaman, Ayesha Shah, Mark Morrison, Natasha Koloski, Kok Gwee, Minhu Chen, Yongsung Kim, Kana Ayaki, Thomas Efferth, Gerald Holtmann

Description:Disorders of gut-brain interaction (DGBI), such as functional dyspepsia (FD) and irritable bowel syndrome (IBS), affect about one-third of the global population. Many patients turn to traditional and herbal medicines for relief, given the lack of effective therapies. This review assesses the clinical and preclinical evidence for herbal treatments used for patients with DGBI. Placebo-controlled trials show that specific herbal preparations, including peppermint oil, ginger, and commercial formulations like STW-5, ZZKZ and Rikkunshito significantly improve gastrointestinal symptoms. Their effectiveness likely arises from various mechanisms, such as alterations in gastrointestinal motility, desensitization of visceral sensory function, and suppression of low-grade mucosal or systemic inflammation. Recent studies of the effects of herbal extracts on the gastrointestinal microbiome also implicate microbial involvement in their effectiveness. Most herbal preparations contain multiple bioactive compounds to address various disease mechanisms, and there remains a significant gap in dose-response studies for optimizing therapeutic outcomes.

Investigating participation in the Australian National Bowel Cancer Screening Program through general practice: a survey on practices, challenges and digital opportunities.

Journal: Public Health Research & Practice
Year: February 20, 2025
Authors: Nicole Marinucci, Natasha Koloski, Amanda Whaley, Rachael Bagnall, Ayesha Shah, Belinda Goodwin, Gerald Holtmann

Description:Objectives Promoting the Australian National Bowel Cancer Screening Program in general practice has been identified as an effective strategy to increase participation rates. Despite the positive influence general practitioners (GPs) have on patient decision-making, program endorsement is not routinely included within the national program's policy and practice. The aim of this study was to gain a comprehensive understanding of knowledge, health promotion strategies and the challenges/opportunities for general practice staff to support patient participation and navigation through the National Bowel Cancer Screening Program pathways. Study type A 52-item online cross-sectional survey. Methods A total of 320 general practice clinics in the Metro South Hospital and Health Service, Queensland, Australia received a direct invitation via email to participate. The survey contained items on knowledge, health promotion strategies and challenges/opportunities to endorse participation in the National Bowel Cancer Screening Program, including enquiry about the utilisation of electronic medical records. Results Eighty-eight individuals participated, including GPs, practice managers and practice nurses. Of GPs, 96.2% indicated they were likely to promote the National Bowel Cancer Screening Program to patients. Few participants used systems to identify/notify patients due for screening, and over half indicated that Medicare reimbursements (56.8%) and electronic systems for identifying eligible or overdue patients (53.4%) would support their ability to promote the National Bowel Cancer Screening Program in routine practice. Conclusion Early detection and treatment of bowel cancer is a public health priority in Australia and internationally. Findings highlight the willingness of staff to promote participation; however, the need for incentivisation and streamlined software integration to identify and prompt eligible patients to screen through the National Bowel Cancer Screening Program remains. These findings contribute new evidence regarding the resources, preferences and system-level requirements needed to support routine GP endorsement of the National Bowel Cancer Screening Program.

Comparison of the Prevalence of Meal-Related Nausea in Different Functional Dyspepsia Subgroups.

Journal: Neurogastroenterology And Motility
Year: January 21, 2025
Authors: Bert Broeders, Esther Colomier, Florencia Carbone, Magnus Simrén, Tao Bai, Jinsong Liu, Chloé Melchior, Guillaume Gourcerol, Kee-huat Chuah, Khoo Hui, Sanjiv Mahadeva, Kewin Tien Siah, Kok-ann Gwee, Peter Lipták, Peter Banovcin, Gerald Holtmann, Natasha Koloski, Marilia Carabotti, Bruno Annibale, Hidekazu Suzuki, Masaya Sano, Takashi Ueda, Hassan Shahoon, Peyman Adibi, Cedric Van De Bruaene, Tim Vanuytsel, Jan Tack

Description:Background: Nausea can coexist in functional dyspepsia (FD) but the literature is poor in reporting whether this symptom is mainly triggered by meal ingestion. Moreover, the prevalence of nausea in FD is understudied. Methods: Adult patients with a disorder of gut-brain interaction (DGBI) recruited in secondary and tertiary care facilities completed the enhanced Asian Rome IV questionnaire with additional questions to address the relationship between nausea and food intake. A comparison of nausea and the prevalence of meal-related nausea was made among FD subgroups and with chronic nausea and vomiting syndrome (CNVS), both according to Rome IV criteria. Results: Of the 1075 DGBI patients that completed the survey, 443 were classified as having FD and 44 other patients fulfilled diagnostic criteria for CNVS. The PDS-EPS overlap group had a higher prevalence of nausea compared to PDS and EPS patients. In PDS patients with nausea, nausea was significantly more often meal-related (than in PDS-EPS overlap, EPS, and CNVS patients). All patients with meal-related nausea reported that nausea started mostly (> 85% of times) within 60 min after the meal. When comparing western and eastern participating centers, nausea was more prevalent in patients from western sites. Conclusions: Nausea is a highly prevalent symptom in FD with a higher prevalence in the PDS-EPS overlap group. However, meal-related nausea is more common in PDS. The pathophysiology of nausea in FD and its implication for medical treatment require further studies.

Clinical Trials by Gerald J. Holtmann

A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3

Enrollment Status: Recruiting

Published: February 25, 2025

Intervention Type: Drug

Study Drug: Mirikizumab

Study Phase: Phase 3

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

Enrollment Status: Completed

Published: May 31, 2025

Intervention Type: Drug

Study Drug: Mirikizumab

Study Phase: Phase 3

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)

Enrollment Status: Completed

Published: February 04, 2025

Intervention Type: Drug

Study Drug: Mirikizumab

Study Phase: Phase 3

A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo-Controlled Study of LY3074828 in Subjects With Active Crohn's Disease (SERENITY)

Enrollment Status: Completed

Published: August 30, 2022

Intervention Type: Drug

Study Drug: Mirikizumab

Study Phase: Phase 2

A Phase 2 Randomized, Double-blind, Placebo-controlled Study in HLA-DQ2.5+ Adults With Celiac Disease to Assess the Effect of Nexvax2 on Symptoms After Masked Gluten Food Challenge

Enrollment Status: Unknown

Published: March 19, 2019

Intervention Type: Biological

Study Drug: Nexvax2

Study Phase: Phase 2

Frequently Asked Questions About Gerald J. Holtmann

What conditions does Gerald J. Holtmann specialize in treating as a Gastroenterologist?

Gerald J. Holtmann specializes in treating a wide range of gastrointestinal conditions such as acid reflux, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and liver disorders.

What diagnostic procedures does Gerald J. Holtmann perform in his practice?

Gerald J. Holtmann performs diagnostic procedures including endoscopy, colonoscopy, and imaging studies to help diagnose and manage gastrointestinal disorders effectively.

How does Gerald J. Holtmann approach treatment plans for his patients?

Gerald J. Holtmann takes a personalized approach to develop treatment plans tailored to each patient's specific condition, considering their medical history, symptoms, and preferences.

What are some common symptoms that patients should not ignore and should consult Gerald J. Holtmann for?

Patients should not ignore symptoms such as persistent abdominal pain, unexplained weight loss, blood in stool, or difficulty swallowing, and should consult Gerald J. Holtmann promptly for evaluation and treatment.

Does Gerald J. Holtmann offer dietary and lifestyle recommendations to manage gastrointestinal conditions?

Yes, Gerald J. Holtmann provides dietary and lifestyle recommendations to help manage gastrointestinal conditions effectively, along with medical treatments when necessary.

How can patients schedule an appointment with Gerald J. Holtmann for a consultation?

Patients can schedule an appointment with Gerald J. Holtmann by contacting his clinic directly via phone or through the online appointment scheduling system available on his website.

More Gastroenterologist Like Gerald J. Holtmann in Woolloongabba

Toparrow